Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis
Φόρτωση...
Ημερομηνία
Συγγραφείς
Golfinopoulos, V.
Pentheroudakis, G.
Salanti, G.
Nearchou, A. D.
Ioannidis, J. P.
Pavlidis, N.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Cancer Treat Rev
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVES: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). DATA SOURCES: PubMed and the Cochrane Library Central Registry of Controlled Trials. REVIEW METHODS: We retrieved all randomized controlled trials comparing at least two arms of different systemic treatment regimens or a systemic regimen to no treatment in patients with CUP, excluding data on favorable subset CUP, whenever these could be separated. Treatments were categorized according to whether they involved platinum, taxane, both, or neither; non-platinum/non-taxane regimens were also categorized in monotherapy and combination regimens. We extracted or estimated the logarithm of the hazard ratio and its variance for death for each randomized comparison. Multiple-treatments meta-analysis with a hierarchical Bayesian model obtained summary hazard ratios with 95% credibility intervals. RESULTS: Ten articles were eligible for the meta-analysis. No trials compared systemic treatment to best supportive care and all arms referred to chemotherapy regimens. Overall 683 subjects were randomly assigned and eight randomized comparisons were used for the multiple-treatments meta-analysis of survival (543 patients). Multiple-treatments meta-analysis showed no significant benefit for any treatment group over others, with wide credibility intervals. Point estimates of hazard ratios favored platinum, taxane, or both (hazard ratios 0.69, 0.66, and 0.81, respectively, as compared with monotherapy with an agent other than platinum or taxane). CONCLUSION: No type of chemotherapy has been solidly proven to prolong survival in patients with CUP. Regimens using either platinum or taxanes or both need further testing.
Περιγραφή
Λέξεις-κλειδιά
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Humans, Neoplasms, Unknown Primary/*drug therapy, Randomized Controlled Trials as Topic, Survival Analysis
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/19539430
http://ac.els-cdn.com/S0305737209000875/1-s2.0-S0305737209000875-main.pdf?_tid=f5fcb96bf08a85b72ecaba1d28a3b12c&acdnat=1333018198_c4152f9b9d584a8bd8d49d9a1853a1cf
http://ac.els-cdn.com/S0305737209000875/1-s2.0-S0305737209000875-main.pdf?_tid=f5fcb96bf08a85b72ecaba1d28a3b12c&acdnat=1333018198_c4152f9b9d584a8bd8d49d9a1853a1cf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής